Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-08-02
2005-08-02
Bui, Phuong T. (Department: 1638)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S258100, C424S093200, C424S093400, C435S252300, C435S252800, C435S879000
Reexamination Certificate
active
06923972
ABSTRACT:
The present invention is directed to mutantSalmonellasp. having a genetically modified msbB gene in which the mutantSalmonellais capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutantSalmonellafor growth inhibition and/or reduction in volume of solid tumors.
REFERENCES:
patent: 4436727 (1984-03-01), Ribi
patent: 5021234 (1991-06-01), Ehrenfeld
patent: 5344762 (1994-09-01), Karapetian
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 5997881 (1999-12-01), Powell et al.
patent: 6251406 (2001-06-01), Haefliger et al.
patent: 2001/0006642 (2001-07-01), Steidler et al.
patent: 2001/0029043 (2001-10-01), Haefliger et al.
patent: 98 94 6891 (1998-09-01), None
patent: WO 92/11361 (1992-07-01), None
patent: WO 95/02048 (1995-01-01), None
patent: WO 96/11277 (1996-04-01), None
patent: WO 96/34631 (1996-11-01), None
patent: WO 96/40238 (1996-12-01), None
patent: WO 96/40238 (1996-12-01), None
patent: WO 97/18837 (1997-05-01), None
patent: WO 97/19688 (1997-06-01), None
patent: WO 97/25061 (1997-07-01), None
Cunningham C. and Nemunaitis J. Hum Gene Ther. 2001;12:1594-6.
MacEwen E. et al., Annual Meeting of the American College of Veterinary Internal Medicine 2001, Abstract 82.
Mier J. et al., Proc. Am. Soc. Clin. Oncol. 2001;20:29 (abstract).
Toso J. et al., J. Clin. Oncol. 2002;20(1):142-52.
Adler, 1973, “A Method for Measuring Chemotaxis and Use of the Method to Determine Optimum Conditions for Chemotaxis byEscherichia coli”, J. Gen. Microbiol. 74:77-91.
Alizadeh et al., 1994, “Apoptosis as a Mechanism of Cytolysis of Tumor Cells by a Pathogenic Free-Living Amoeba”, Infect. Immun. 62:1298-1303.
Anderson et al., 1996, “Development of Attenuated Salmonella Strains the Express Heterologous Antigens”, in:Methods in Molecular Medicine: Vaccine Protocols, Robinson et al., eds., Humana Press, New Jersey, pp. 47-62.
Bagshawe, 1995, “Antibody-Directed Enzyme Prodrug Therapy: A Review”, Drug Dev. Res. 34:220-230.
Barry et al., 1995, “Protection Against Mycoplasma Infection Using Expression-Library Immunization”, Nature 377:632-635.
Barth and Morton, 1995, “The Role of Adjuvant Therapy in Melanoma Management”, Cancer 75 (Suppl.):726-734.
Berggren, 1995, “Recombinant Salmonella as an Oral HIV Vaccine”, NIH Project No. 5 K08 Al01248-02.
Bone, 1993, “Gram-Negative Sepsis: A Dilemma of Modern Medicine”, Clin. Microbiol. Rev. 6:57-68.
Bonnekoh et al., 1995, “Inhibition of Melanoma Growth by Adenoviral-Mediated HSV Thymidine Kinase Gene Transfer in vivo”, J. Invest. Derm. 104:313-317.
Carey etal., “Clostridial Oncolysis in Man”, Eur. J. Cancer 3:37-46.
Carrier et al., 1992, “Expression of Human IL-1β inSalmonella typhimurium; a Model System for the Delivery of Recombinant Therapeutic Proteins in vivo”, J. Immunol. 148:1176-1181.
Carswell et al., 1975, “An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors”, Proc. Natl. Acad. Sci. USA 72:3666-3670.
Chabalgoity et al., 1996, “ASalmonella typhimurium htrALive Vaccine Expressing Multiple Copies of a Peptide Comprising Amino Acids 8-23 of Herpes Simplex Virus Glycoprotein D as a Genetic Fusion to Tetanus Toxin Fragment C Protects Mice from Herpes Simplex Virus Infection”, Mol. Microbiol. 19:791-801.
Christ et al., 1995, “E5531, a Pure Endotoxin Antagonist of High Potency”, Science 268:80-83.
Clements, 1995, “Attenuated Salmonella as Vaccine Vectors”, NIH Project No. 5 R01 Al 28835-06.
Clementz et al., 1997, “Function of theEscherichia coli msbBGene, a Multicopy Suppressor of htrB Knockouts, in the Acylation of Lipid A”, J. Biol. Chem. 272(16):10353-10360.
Cunningham et al., 1992, “Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion”, Science 255:325-327.
Curtiss, 1995, “Biological Containment of Live Bacterial Vaccines”, NIH Project No. 1 R41 Al38599-01.
Curtiss, 1994, “Avirulent Salmonella Host-Vector Vaccine Systems”, NIH Project No. R41 Al36585-01.
Eisenstadt, 1987, “Analysis of Mutagenesis”, fromEscherichia coli and Salmonella typhimurium, Cellular and Molecular Biology, Neidhardt et al. (ed.), pp. 1016-1033.
Eisenstein et al., 1995, “Immunotherapy of a Plasmacytoma with Attenuated Salmonella”, Med. Oncol. 12:103-108.
Engel et al., 1992, “Murein-Metabolizing Enzymes fromEscherichia coli: Existence of a Second Lytic Transglycosylase”, J. Bacteriol. 174:6394-6403.
Engelbart and Gericke, 1963, “Oncolysis by Clostridia. V. Transplanted Tumors of the Hamster”, Cancer Res. 24:239-243.
Falkow, 1991, “Bacterial Entry into Eukaryotic Cell”, Cell 65:1099-1102.
Fields et al., 1989, “A Salmonella Locus that Controls Resistance to Microbicidal Proteins from Phagocytic Cells”, Science 243:1059-1062.
Fields et al., 1986, “Mutants ofSalmonella typhimuriumthat Cannot Survive within the Macrophage are Avirulent”, Proc. Natl. Acad. Sci. USA 83:5189-5193.
Fox et al., 1996, “Anaerobic Bacteria as a Delivery System for Cancer Gene Therapy: in vitro Activation of 5-Fluorocytosine by Genetically Engineered Clostridia”, Gene Therapy 3:173-178.
Friberg, 1993, “BCG in the Treatment of Superficial Cancer of the Bladder: A Review”, Med. Oncol. Tumor Pharmacother. 10:31-36.
Galan, 1995, “Novel Salmonella Antigen Delivery Vectors”, NIH Project No. 5 R01 Al36520-02.
Gericke and Engelbart, 1963, “Oncolysis by Clostridia. II. Experiments on a Tumor Spectrum with a Variety of Clostridia in Combination with Heavy Metal”, Cancer Res. 24:217-221.
Gulig, 1994, “Salmonella typhimuriumVirulence Plasmid”, NIH Project No. 5 R29 Al28421-05.
Hall et al., 1994, “Induced Regression of Bovine Papillomas by Intralesional Immunotherapy”, Therarpeutic Immunol. 1:319-324.
Han et al., 1967, “Salmonellosis in Disseminated Malignant Diseases”, New Eng. J. Med. 276:1045-1052.
Hoiseth and Stocker, 1981, “Aromatic-DependentSalmonella typhimuriumare Non-Virulent and Effective as Live Vaccines”, Nature 291: 238-239.
Jain, 1994, “Barriers to Drug Delivery in Solid Tumors”, Sci. American 271:58-65.
Jones et al., 1992, “Invasion bySalmonella typhimuriumis Affected by the Direction of Flagellar Rotation”, Infect. Immun. 60:2475-2480.
Karow and Georgopoulos, 1992, “Isolation and Characterization of theEscherichia coli msbBGene, a Multicopy Suppressor of Null Mutations in the High-Temperature Requirement Gene htrB”, J. Bacteriol. 174:702-710.
Kelly et al., 1993, “The firA Gene ofEscherichia coliEncodes UDP-3-0-(R-3-hydroxymyristoyl)-Glucosamine N-Acyltransferase”, J. Biol. Chem. 268:19866-19874.
King et al., 1998, “Tumor Targeted Salmonella Expressing Cytosine Deaminase Converted 5-Fluorocytosine to 5-Fluorouracil and Inhibited Tumor Growth in vivo”, Proc. Amer. Assoc. for Cancer Res. 39:512.
Klimpel et al., 1990, “Bacteria-Infected Fibroblasts Have Enhanced Susceptibility to the Cytotoxic Action of Tumor Necrosis Factor”, J. Immunol. 145:711-717.
Lee et al., 1992, “Identification of aSalmonella typhimuriumInvasion Locus by Selection for Hyperinvasive Mutants”, Proc. Natl. Acad. Sci. USA 89:1847-1851.
Lemmon et al., 1994, “Anaerobic Bacteria as a Gene Delivery System to Tumors”, Proc. Am. Assn. Cancer Res. 35:374 (Abstract 2231).
Lemmon et al., 1997, “Anaerobic Bacteria as a Gene Delivery System that is Controlled by the Tumor Microenvironment”, Gene Therapy 4:791-796.
Levine, 1995, “Recombinant and Live OralSalmonella typhiVaccines”, NIH Project No. 5 R01 Al29471-06.
Lindgren et al., 1996, “Macrophage Killing Is an Essential Virulence Mechanism ofSalmonella
Bermudes David
Low Kenneth Brooks
Bui Phuong T.
Law Offices of Albert Wai-Kit Chan LLC
Vion Pharmaceuticals Inc.
LandOfFree
Methods for use of genetically modified tumor-targeted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for use of genetically modified tumor-targeted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for use of genetically modified tumor-targeted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3522899